Jean-Paul Clozel
Chief Executive Officer presso IDORSIA LTD
Profilo
Fondatore di Actelion Ltd., Jean-Paul Clozel occupa attualmente la posizione di presidente di Idorsia Pharmaceuticals Ltd. e di amministratore delegato e direttore di Idorsia Ltd. In passato il Dr. Clozel ha ricoperto la posizione di Chief Executive Officer & Executive Director presso Actelion Ltd., Chief Executive Officer di Actelion Pharmaceuticals UK Ltd. e Head-Drug Discovery Group presso F. Hoffmann-La Roche Ltd.
Posizioni attive di Jean-Paul Clozel
Società | Posizione | Inizio |
---|---|---|
IDORSIA LTD | Chief Executive Officer | 01/06/2017 |
Idorsia Pharmaceuticals Ltd.
Idorsia Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Part of Idorsia Ltd., Idorsia Pharmaceuticals Ltd. is a Swiss company that aims to discover, develop, and provide innovative medicines to patients. The private company is based in Allschwil, Switzerland. The company has created an eBook that provides useful information about Fabry disease, a rare inherited disorder caused by the build-up of a fat-like substance in the cells of the body organs. Jean-Paul Clozel has been the CEO of the company since 2017. | Chief Executive Officer | 01/01/2017 |
Precedenti posizioni note di Jean-Paul Clozel
Società | Posizione | Fine |
---|---|---|
ACTELION | Founder | 16/06/2017 |
F. Hoffmann-La Roche Ltd.
F. Hoffmann-La Roche Ltd. Pharmaceuticals: MajorHealth Technology F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland. | Corporate Officer/Principal | 01/01/1997 |
Idorsia Pharmaceuticals Ltd.
Idorsia Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Part of Idorsia Ltd., Idorsia Pharmaceuticals Ltd. is a Swiss company that aims to discover, develop, and provide innovative medicines to patients. The private company is based in Allschwil, Switzerland. The company has created an eBook that provides useful information about Fabry disease, a rare inherited disorder caused by the build-up of a fat-like substance in the cells of the body organs. Jean-Paul Clozel has been the CEO of the company since 2017. | Chairman | - |
Actelion Pharmaceuticals UK Ltd.
Actelion Pharmaceuticals UK Ltd. Medical DistributorsDistribution Services Actelion Pharmaceuticals UK Ltd. discovers, develops, and markets drugs. Its products are Tracleer for the treatment of pulmonary arterial hypertension and Zavesca, which is used to treat Type 1 Gaucher disease. The company is headquartered in London, UK. | Chief Executive Officer | - |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 1 |
---|---|
IDORSIA LTD | Health Technology |
Aziende private | 4 |
---|---|
F. Hoffmann-La Roche Ltd.
F. Hoffmann-La Roche Ltd. Pharmaceuticals: MajorHealth Technology F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland. | Health Technology |
Actelion Ltd.
Actelion Ltd. Pharmaceuticals: MajorHealth Technology Actelion Ltd. develops, produces and markets pharmaceutical drugs. The firm engages in research, development, manufacturing, and distribution of pharmaceutical, biological, and diagnostic products. The company was founded by Jean-Paul Clozel, Martine Clozel, Walter Fischli, André J. Müller and Thomas Widmann on December 30, 1999 and is headquartered in Allschwil, Switzerland. | Health Technology |
Actelion Pharmaceuticals UK Ltd.
Actelion Pharmaceuticals UK Ltd. Medical DistributorsDistribution Services Actelion Pharmaceuticals UK Ltd. discovers, develops, and markets drugs. Its products are Tracleer for the treatment of pulmonary arterial hypertension and Zavesca, which is used to treat Type 1 Gaucher disease. The company is headquartered in London, UK. | Distribution Services |
Idorsia Pharmaceuticals Ltd.
Idorsia Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Part of Idorsia Ltd., Idorsia Pharmaceuticals Ltd. is a Swiss company that aims to discover, develop, and provide innovative medicines to patients. The private company is based in Allschwil, Switzerland. The company has created an eBook that provides useful information about Fabry disease, a rare inherited disorder caused by the build-up of a fat-like substance in the cells of the body organs. Jean-Paul Clozel has been the CEO of the company since 2017. | Health Technology |
- Borsa valori
- Insiders
- Jean-Paul Clozel